Empowering personalized
treatment decisions
for cancer patients

Identify the right therapy with StrandAdvantage

StrandAdvantage enables oncologists to personalize cancer treatment for patients by providing information about therapies that are likely to be most effective, and those that are likely to be ineffective.

Information on therapy response is obtained by sequencing a patient’s tumor to measure genomic alterations or protein expression levels. This molecular information is analyzed using bioinformatics algorithms in conjunction with curated data from peer-reviewed clinical studies to select the right therapy, and treat the cancer effectively.

StrandAdvantage offers a comprehensive range of testing options based on the treatment requirement for the patient – the StrandAdvantage TST, 56-gene test, and 152-gene test.

StrandAdvantage Tissue-specific Test (TST)

Enabling cancer tissue-specific standard-of-care therapy decisions

  • Comprehensive therapy suggestions

    The TST primarily provides information on drug response for FDA approved targeted therapy and chemotherapy. Immunotherapies are suggested for certain tumors.

  • Common cancer types covered

    StrandAdvantage TST can be used for testing the following:

    • lungNon-Small Cell Lung Carcinoma (NSCLC)
    • colonColorectal Carcinoma
    • breastBreast Carcinoma
  • How are therapy recommendations made?

    Therapy recommendations are made based on the mutation status of genomic markers or expression level of biomarkers.

  • Are the markers guideline recommended for testing?

    Most of the standard markers are recommended for testing by guidelines. Certain emerging markers are tested based on clinical evidence from large studies.

  • Comprehensive multi-platform testing

    StrandAdvantage uses a comprehensive approach of the following platforms to analyse the tumor for markers.

    • NGSNGS
    • fishFISH
    • IHCIHC
  • Turnaround Time

    timeThe TST report is delivered in 10 working days

  • Sample requirements

    Formalin-fixed, paraffin embedded tissue (FFPE)

StrandAdvantage 56-gene Test

Expanding treatment options for patients

  • Targeted therapy and clinical trials

    The StrandAdvantage 56-gene test provides information on targeted therapies that are approved for use or therapies in clinical trials.

  • Cancer types covered

    The Strand 56-gene test can be used to test the following:

    • Tumors of unknown primary origin
    • Metastatic and refractory cancers
    • Rare and aggressive cancers
  • When can the StrandAdvantage 56-gene test be ordered?

    The StrandAdvantage 56-gene test can be ordered in the following situations:

    • No actionable mutation is found from preliminary testing
    • Disease progression after first or second line standard-of-care therapy
    • Patients looking to enroll for clinical trial options
  • Test method
    • NGS
  • Turnaround Time

    timeThe 56-gene test report is delivered in 15-20 working days

  • Sample requirement

    Formalin-fixed, paraffin embedded tissue (FFPE)

Learn more about the StrandAdvantage 56-gene test

StrandAdvantage 152-gene Test

The most comprehensive genomic profiling test

  • What therapy information does the StrandAdvantage 152-gene Test provide?

    The StrandAdvantage 152-gene test provides information on targeted therapies that are approved for use, and comprehensive information on investigational therapies in clinical trials.

  • When can the StrandAdvantage 152-gene Test be ordered?

    The StrandAdvantage 152 gene test covers a comprehensive range of genes involved in cancer pathways. This test can be ordered in cases where no mutations were found in preliminary or guideline recommended for late-stage, metastatic and rare cancers.

  • What types of gene alterations can be detected using the StrandAdvantage 152-gene Test?

    The 152-gene test is not a hot-spot based gene test. It can detect a wide variety of somatic gene alterations such as single nucleotide variations (SNVs), InDels (insertions & deletions), copy number changes, and gene rearrangements and fusions.

  • Test method
    • NGSNGS
  • Turnaround Time

    time6-8 weeks

  • Sample requirement

    Formalin-fixed, paraffin embedded tissue (FFPE)

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and

understand our Cookie Policy , Privacy Policy and our Terms of Service.